Diagnoses we work with
Full catalogue of oncology diagnoses for which we help arrange treatment in China.
Haematologic malignancies
Diffuse large B-cell lymphoma (DLBCL)
The most common aggressive non-Hodgkin lymphoma in adults. Modern treatment includes R-CHOP, CAR-T and bispecific antibodies.
Read more →Follicular lymphoma
An indolent B-cell lymphoma. CAR-T is used in relapsed and refractory disease.
Read more →Mantle-cell lymphoma
A rare aggressive B-cell lymphoma. CAR-T is approved after relapse on BTK inhibitors.
Read more →Burkitt lymphoma
A highly aggressive B-cell lymphoma requiring intense short-course chemotherapy and rapid escalation.
Read more →B-cell acute lymphoblastic leukaemia (B-ALL)
A leading indication for CAR-T in children and young adults.
Read more →Multiple myeloma
BCMA-directed CAR-T and bispecifics have transformed late-line treatment.
Read more →Common solid tumours
Breast cancer
One of the most common cancers in women. Treatment depends on molecular profile (ER/PR/HER2).
Read more →Lung cancer
The leading cause of cancer death worldwide. Treatment depends on histology (NSCLC vs. SCLC) and molecular markers (EGFR, ALK, ROS1, KRAS G12C).
Read more →Colorectal cancer
Screening is decisive. Molecular subtypes (MSI-H, RAS, BRAF) drive targeted and immune therapy choice.
Read more →Prostate cancer
A hormone-sensitive cancer with a long natural history. Modern options include PSMA-targeted therapy and PARP inhibitors.
Read more →Hepatocellular carcinoma (liver cancer)
Local methods (TACE, ablation), immunotherapy and targeted therapy.
Read more →Kidney cancer
Responsive to checkpoint inhibitors and anti-VEGF therapy.
Read more →Cervical cancer
HPV-associated. Screening and vaccination are key preventive measures.
Read more →Ovarian cancer
Often diagnosed at advanced stages. PARP inhibitors are standard in BRCA-mutated disease.
Read more →Gastrointestinal and abdominal tumours
Gastric cancer
High incidence in East Asia. Modern options — HER2 targeting, immunotherapy, CLDN18.2.
Read more →Pancreatic cancer
One of the most difficult tumours. FOLFIRINOX, gem/nab-paclitaxel, trials with CAR-T and vaccines.
Read more →Oesophageal cancer
Combined-modality treatment is central. Modern approaches include neoadjuvant immunotherapy.
Read more →Gastrointestinal stromal tumours (GIST)
KIT/PDGFRA drivers. Imatinib and subsequent TKI lines transformed prognosis.
Read more →Primary peritoneal carcinomas
Rare tumours of the peritoneum. Cytoreductive surgery with HIPEC is often considered.
Read more →Mesothelioma
Asbestos-related. Combination immunotherapy is now first-line standard.
Read more →Sarcomas and bone tumours
Osteosarcoma
The most common primary malignant bone tumour in young patients.
Read more →Ewing sarcoma
Aggressive tumour of children and adolescents. High-intensity combined regimens.
Read more →Chondrosarcoma
A tumour of cartilaginous origin. Limited sensitivity to radiation and chemo — surgery is the mainstay.
Read more →Giant-cell tumour of bone
Locally aggressive, rarely metastasises. Denosumab is the standard systemic option.
Read more →Soft-tissue sarcomas
A heterogeneous group of 70+ subtypes. Treatment is dictated by histology and location.
Read more →Bone metastases
Local methods (radiation, ablation) plus systemic and supportive care.
Read more →Skin cancers
Melanoma
One of the most aggressive skin cancers. Early-stage disease is highly curable surgically.
Read more →Basal-cell carcinoma
The most common skin cancer. Local treatment, rare metastasis.
Read more →Cutaneous squamous-cell carcinoma
Common on sun-exposed sites. Immunotherapy is an option for advanced disease.
Read more →Kaposi sarcoma
HHV-8 associated. In HIV-positive patients, antiretroviral therapy is the foundation.
Read more →Dermatofibrosarcoma protuberans
A low-grade cutaneous tumour. Mohs surgery is the procedure of choice.
Read more →Paediatric oncology
Acute leukaemia (paediatric)
Paediatric B-ALL and AML — high survival rates with modern protocols.
Read more →Rhabdomyosarcoma
The most common soft-tissue sarcoma in children.
Read more →Retinoblastoma
The most common intraocular tumour in children. Modern approaches preserve vision in the majority.
Read more →Neuroblastoma
The most common extracranial solid tumour of early childhood.
Read more →Wilms tumour (nephroblastoma)
The most common kidney tumour in children. High cure rates.
Read more →Rare and neuroendocrine
Neuroendocrine tumours (NETs, GEP-NETs)
A heterogeneous tumour family. PRRT (177Lu-DOTATATE) is targeted peptide-receptor radionuclide therapy.
Read more →Carcinoid tumours
Well-differentiated neuroendocrine tumours. Somatostatin analogues anchor symptomatic management.
Read more →Cancer of unknown primary (CUP)
Metastatic disease without an identified primary. Molecular profiling guides treatment direction.
Read more →Germ-cell tumours
Highly sensitive to platinum chemotherapy. Curable even at advanced stages.
Read more →Gestational trophoblastic disease
Rare but highly curable. Methotrexate and combination regimens.
Read more →Systemic autoimmune disease (SLE and others)
CAR-T therapy is being actively studied in severe refractory SLE, systemic sclerosis and myositis.
Read more →Tell us about your case — we will call you back.
A free consultation. Reply within one business day. No commitment.